Literature DB >> 22728071

DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes.

Mao Zhao1,2, Luan Xiaofei1, Cao Gang2, Liu Wei1, Xiong Jing1, Hu Gang1, Chen Ruini1, Ning Rui1, Shang Wei1, Yang Jian1, Yan Bingfang3.   

Abstract

In this study, we provided molecular evidences that interleukin-6 (IL-6) contributed to the decreased capacity of oxidative biotransformation in human liver by suppressing the expression of cytochrome P450 3A4 (CYP3A4). After human hepatocytes were treated with IL-6, differentially expressed in chondrocytes 1 (DEC1) expression rapidly increased, and subsequently, the CYP3A4 expression decreased continuously. Furthermore, the repression of CYP3A4 by IL-6 occurred after the increase of DEC1 in primary human hepatocytes. In HepG2 cells, knockdown of DEC1 increased the CYP3A4 expression and its enzymatic activity. In addition, it partially abolished the decreased CYP3A4 expression as well as its enzymatic activity induced by IL-6. Consistent with this, overexpression of DEC1 markedly reduced the CYP3A4 promoter activity and the CYP3A4 expression as well as its enzymatic activity. Using sequential truncation and site directed mutagenesis of CYP3A4 proximal promoter with DEC1 construct, we showed that DEC1 specifically bound to CCCTGC sequence in the proximal promoter of CYP3A4, which was validated by EMSA and ChIP assay. These findings suggest that the repression of CYP3A4 by IL-6 is achieved through increasing the DEC1 expression in human hepatocytes, the increased DEC1 binds to the CCCTGC sequence in the promoter of CYP3A4 to form CCCTGC-DEC1 complex, and the complex downregulates the CYP3A4 expression and its enzymatic activity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728071      PMCID: PMC4088276          DOI: 10.1016/j.bcp.2012.06.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  49 in total

1.  Molecular cloning and characterization of DEC2, a new member of basic helix-loop-helix proteins.

Authors:  K Fujimoto; M Shen; M Noshiro; K Matsubara; S Shingu; K Honda; E Yoshida; K Suardita; Y Matsuda; Y Kato
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

Review 2.  Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies.

Authors:  Antti Poso; Paavo Honkakoski
Journal:  Mini Rev Med Chem       Date:  2006-08       Impact factor: 3.862

3.  Elevation of cytokines in peritoneal fluid and blood in patients with liver cirrhosis.

Authors:  A S Eriksson; C Gretzer; S Wallerstedt
Journal:  Hepatogastroenterology       Date:  2004 Mar-Apr

4.  Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment.

Authors:  Xuexian O Yang; Pornpimon Angkasekwinai; Jinfang Zhu; Juan Peng; Zhiduo Liu; Roza Nurieva; Xikui Liu; Yeonseok Chung; Seon Hee Chang; Bing Sun; Chen Dong
Journal:  Nat Immunol       Date:  2009-11-01       Impact factor: 25.606

5.  A novel autofeedback loop of Dec1 transcription involved in circadian rhythm regulation.

Authors:  Takeshi Kawamoto; Mitsuhide Noshiro; Fuyuki Sato; Koji Maemura; Norihiko Takeda; Ryozo Nagai; Tomoyuki Iwata; Katsumi Fujimoto; Masae Furukawa; Kazuko Miyazaki; Sato Honma; Ken ichi Honma; Yukio Kato
Journal:  Biochem Biophys Res Commun       Date:  2004-01-02       Impact factor: 3.575

6.  Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression.

Authors:  Beth W Cooper; Taehyeon M Cho; Peter M Thompson; Andrew D Wallace
Journal:  Toxicol Sci       Date:  2008-03-10       Impact factor: 4.849

7.  Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.

Authors:  Anne P Beigneux; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

8.  Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis.

Authors:  Wei Zhang; Bei Yue; Gui-Qiang Wang; Shu-Lan Lu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2002-11

9.  Regulation of lipogenesis via BHLHB2/DEC1 and ChREBP feedback looping.

Authors:  Katsumi Iizuka; Yukio Horikawa
Journal:  Biochem Biophys Res Commun       Date:  2008-07-09       Impact factor: 3.575

10.  Simultaneous substitution of phenylalanine-305 and aspartate-318 of rat pregnane X receptor with the corresponding human residues abolishes the ability to transactivate the CYP3A23 promoter.

Authors:  Xiulong Song; Yuxin Li; Jirong Liu; Madhu Mukundan; Bingfang Yan
Journal:  J Pharmacol Exp Ther       Date:  2004-09-14       Impact factor: 4.030

View more
  3 in total

1.  Role of Systemic Lupus Erythematosus Risk Variants With Opposing Functional Effects as a Driver of Hypomorphic Expression of TNIP1 and Other Genes Within a Three-Dimensional Chromatin Network.

Authors:  Satish Pasula; Kandice L Tessneer; Yao Fu; Jaanam Gopalakrishnan; Richard C Pelikan; Jennifer A Kelly; Graham B Wiley; Mandi M Wiley; Patrick M Gaffney
Journal:  Arthritis Rheumatol       Date:  2020-03-30       Impact factor: 10.995

2.  Effect of the active ingredient of Kaempferia parviflora, 5,7-dimethoxyflavone, on the pharmacokinetics of midazolam.

Authors:  Wataru Ochiai; Hiroko Kobayashi; Satoshi Kitaoka; Mayumi Kashiwada; Yuya Koyama; Saho Nakaishi; Tomomi Nagai; Masaki Aburada; Kiyoshi Sugiyama
Journal:  J Nat Med       Date:  2018-03-17       Impact factor: 2.343

3.  Interleukin-6 Induces DEC1, Promotes DEC1 Interaction with RXRα and Suppresses the Expression of PXR, CAR and Their Target Genes.

Authors:  Rui Ning; Yunran Zhan; Shuangcheng He; Jinhua Hu; Zhu Zhu; Gang Hu; Bingfang Yan; Jian Yang; Wei Liu
Journal:  Front Pharmacol       Date:  2017-11-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.